Treatment-related adverse events
| TRAEs | Any grade n (%) | Grade 1–2 n | Grade 3–4 n | Grade 5 n | |
| Any | 30 (100) | 30 | 21 | 1 | |
| Dermatitis/rash | 24 (80) | 22 | 2 | 0 | |
| Appetite loss/nausea/vomiting | 21 (70) | 19 | 2 | 0 | |
| Anemia | 21 (70) | 19 | 2 | 0 | |
| Fatigue | 18 (60) | 17 | 1 | 0 | |
| Transaminitis/hepatitis | 17 (57) | 13 | 4 | 0 | |
| Leukopenia | 17 (57) | 10 | 7 | 0 | |
| Esophagitis | 16 (53) | 15 | 1 | 0 | |
| Electrolyte disorders | 16 (53) | 15 | 1 | 0 | |
| Constipation/diarrhea | 16 (53) | 16 | 0 | 0 | |
| Thrombocytopenia | 14 (47) | 9 | 5 | 0 | |
| Pain | 13 (43) | 13 | 0 | 0 | |
| Alk Phos increased | 11 (37) | 11 | 0 | 0 | |
| Thyroid disorders | 10 (33) | 10 | 0 | 0 | |
| Dyspnea | 10 (33) | 7 | 3 | 0 | |
| Cough | 10 (33) | 10 | 0 | 0 | |
| GGT increased | 8 (27) | 6 | 2 | 0 | |
| Fever | 6 (20) | 6 | 0 | 0 | |
| Nervous disorders | 5 (17) | 5 | 0 | 0 | |
| Lymphopenia | 5 (17) | 4 | 1 | 0 | |
| LDH increased | 5 (17) | 5 | 0 | 0 | |
| Pneumonitis | 4 (13) | 2 | 1 | 1 | |
| Dry skin | 4 (13) | 4 | 0 | 0 | |
| Insomnia | 3 (10) | 3 | 0 | 0 | |
| Infusion-related reaction | 3 (10) | 3 | 0 | 0 | |
| CRP increased | 3 (10) | 3 | 0 | 0 | |
| irAEs | |||||
| Any | 20 (67) | 16 | 6 | 1 | |
| Thyroid disorders | 10 (33) | 10 | 0 | 0 | |
| Dermatitis/rash | 9 (30) | 7 | 2 | 0 | |
| Pneumonitis | 3 (10) | 2 | 0 | 1 | |
| Transaminitis/hepatitis | 2 (7) | 0 | 2 | 0 | |
| Pericarditis | 1 (3) | 1 | 0 | 0 | |
| Pancreatitis | 1 (3) | 0 | 1 | 0 | |
| Myositis | 1 (3) | 0 | 1 | 0 | |
| Allergic reaction | 1 (3) | 1 | 0 | 0 |
TRAEs monitored in all 30 patients commencing with induction therapy, and occurring in 10% or more of patients, in the period from the start of therapy until 90 days post-surgery or if no surgery was performed until 180 days after the start of therapy, are shown in the top part. In the bottom part, irAEs are shown.
CRP, C-reactive protein; GGT, gamma glutamyl transferase; irAE, immune-related adverse events; LDH, lactate dehydrogenase; TRAE, treatment-related adverse events.